Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2015 1
2016 3
2018 1
2019 2
2020 4
2021 2
2022 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Rosenblatt's First Theorem and Frugality of Deep Learning.
Kirdin A, Sidorov S, Zolotykh N. Kirdin A, et al. Among authors: sidorov s. Entropy (Basel). 2022 Nov 10;24(11):1635. doi: 10.3390/e24111635. Entropy (Basel). 2022. PMID: 36359726 Free PMC article.
Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors.
Kurilin V, Kulikova E, Shevchenko J, Lopatnikova J, Obleukhova I, Khantakova J, Maksyutov A, Kuznetsova M, Khristin A, Kiryshina N, Kozlov V, Sidorov S, Sokolov A, Vitsin A, Shiku H, Sennikov S. Kurilin V, et al. Among authors: sidorov s. Mol Clin Oncol. 2022 Oct 3;17(5):155. doi: 10.3892/mco.2022.2588. eCollection 2022 Nov. Mol Clin Oncol. 2022. PMID: 36325297 Free PMC article.
Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.
Ruzanova V, Proskurina A, Efremov Y, Kirikovich S, Ritter G, Levites E, Dolgova E, Potter E, Babaeva O, Sidorov S, Taranov O, Ostanin A, Chernykh E, Bogachev S. Ruzanova V, et al. Among authors: sidorov s. Pathol Oncol Res. 2022 May 27;28:1610180. doi: 10.3389/pore.2022.1610180. eCollection 2022. Pathol Oncol Res. 2022. PMID: 35693632 Free PMC article.
Karanahan: A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.
Proskurina AS, Kupina VV, Efremov YR, Dolgova EV, Ruzanova VS, Ritter GS, Potter EA, Kirikovich SS, Levites EV, Ostanin AA, Chernykh ER, Babaeva OG, Sidorov SV, Bogachev SS. Proskurina AS, et al. Among authors: sidorov sv. Breast Cancer (Auckl). 2022 Feb 14;16:11782234211059931. doi: 10.1177/11782234211059931. eCollection 2022. Breast Cancer (Auckl). 2022. PMID: 35185333 Free PMC article.
Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02:01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients.
Sennikov SV, Shevchenko JA, Kurilin VV, Khantakova JN, Lopatnikova JA, Gavrilova EV, Maksyutov RA, Bakulina AY, Sidorov SV, Khristin AA, Maksyutov AZ. Sennikov SV, et al. Among authors: sidorov sv. Immunol Res. 2016 Feb;64(1):171-80. doi: 10.1007/s12026-015-8735-0. Immunol Res. 2016. PMID: 26590947
Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2016 Feb 17;16:117. doi: 10.1186/s12885-016-2163-y. BMC Cancer. 2016. PMID: 26887451 Free PMC article. No abstract available.
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
Proskurina AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, Orishchenko KE, Nikolin VP, Popova NA, Sidorov SV, Chernykh ER, Ostanin AA, Leplina OY, Dvornichenko VV, Ponomarenko DM, Soldatova GS, Varaksin NA, Ryabicheva TG, Uchakin PN, Zagrebelniy SN, Rogachev VA, Bogachev SS, Shurdov MA. Proskurina AS, et al. Among authors: sidorov sv. BMC Cancer. 2015 Mar 13;15:122. doi: 10.1186/s12885-015-1142-z. BMC Cancer. 2015. PMID: 25886605 Free PMC article. Clinical Trial.
18 results